ISD 017
Alternative Names: ISD-017Latest Information Update: 04 Dec 2020
At a glance
- Originator ISD Immunotech
- Class Anti-inflammatories; Peptides; Skin disorder therapies
- Mechanism of Action MPYS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Systemic lupus erythematosus
Most Recent Events
- 27 Nov 2020 ISD Immunotech entered an agreement with Biogen for the development of ISD 017
- 27 Nov 2020 ISD Immunotech intends to submit orphan drug designation application to US FDA and EMA for the treatment of systemic lupus erythematosus
- 24 Nov 2020 Preclinical trials in Systemic lupus erythematosus in Denmark (Intraperitoneal)